Disrupting specific PDZ domain-mediated interactions for therapeutic benefitHOUSLAY, Miles D.British journal of pharmacology. 2009, Vol 158, Num 2, pp 483-485, issn 0007-1188, 3 p.Article

Phosphodiesterases as Drug TargetsHOUSLAY, Miles D; CONTI, Marco; FRANCIS, Sharron H et al.Handbook of experimental pharmacology. 2011, Vol 204, issn 0171-2004, 531 p.Serial Issue

Phosphodiesterase Inhibitors: Factors That Influence Potency, Selectivity, and ActionFRANCIS, Sharron H; HOUSLAY, Miles D; CONTI, Marco et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 47-84, issn 0171-2004, 38 p.Article

Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in ratsMAKHAY, Malath M; HOUSLAY, Miles D; O'DONNELL, James M et al.Psychopharmacologia. 2001, Vol 158, Num 3, pp 297-304, issn 0033-3158Article

Phosphodiesterase-4 as a therapeutic targetHOUSLAY, Miles D; SCHAFER, Peter; ZHANG, Kam Y. J et al.Drug discovery today. 2005, Vol 10, Num 22, pp 1503-1519, issn 1359-6446, 17 p.Article

cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system : A molecular toolbox for generating compartmentalized cAMP signalingHOUSLAY, Miles D; BAILLIE, George S; MAURICE, Donald H et al.Circulation research. 2007, Vol 100, Num 7, pp 950-966, issn 0009-7330, 17 p.Article

Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase InhibitorsUCKERT, Stefan; STIEF, Christian G.Handbook of experimental pharmacology. 2011, Vol 204, pp 307-322, issn 0171-2004, 16 p.Article

Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary HypertensionFARROW, Kathryn N; STEINHORN, Robin H.Handbook of experimental pharmacology. 2011, Vol 204, pp 251-277, issn 0171-2004, 27 p.Article

Phosphodiesterases as Targets for Modulating T-Cell ResponsesBJØRGO, Elisa; MOLTU, Kristine; TASKEN, Kjetil et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 345-363, issn 0171-2004, 19 p.Article

Phosphodiesterase Inhibitors in the Treatment of Inflammatory DiseasesPAGE, C. P; SPINA, D.Handbook of experimental pharmacology. 2011, Vol 204, pp 391-414, issn 0171-2004, 24 p.Article

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cellsSHEPHERD, Malcolm C; BAILLIE, George S; STIRLING, David I et al.British journal of pharmacology. 2004, Vol 142, Num 2, pp 339-351, issn 0007-1188, 13 p.Article

Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterasesBAILLIE, George S; MACKENZIE, Simon J; MCPHEE, Ian et al.British journal of pharmacology. 2000, Vol 131, Num 4, pp 811-819, issn 0007-1188Article

Structural Insight into the Substrate Specificity of PhosphodiesterasesHENGMING KE; HUANCHEN WANG; MENGCHUN YE et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 121-134, issn 0171-2004, 14 p.Article

Regulation of Endothelial Barrier Function by Cyclic Nucleotides: The Role of PhosphodiesterasesSURAPISITCHAT, James; BEAVO, Joseph A.Handbook of experimental pharmacology. 2011, Vol 204, pp 193-210, issn 0171-2004, 18 p.Article

Phosphodiesterase Inhibition in Heart FailureMOVSESIAN, Matthew A; KUKREJA, Rakesh C.Handbook of experimental pharmacology. 2011, Vol 204, pp 237-249, issn 0171-2004, 13 p.Article

Cyclic Nucleotides and Phosphodiesterases in Monocytic DifferentiationHERTZ, Angie L; BEAVO, Joseph A.Handbook of experimental pharmacology. 2011, Vol 204, pp 365-390, issn 0171-2004, 26 p.Article

Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination TherapiesGIEMBYCZ, Mark A; NEWTON, Robert.Handbook of experimental pharmacology. 2011, Vol 204, pp 415-446, issn 0171-2004, 32 p.Article

Phosphodiesterases as Targets for Intermittent ClaudicationYONGGE LIU; SHAKUR, Yasmin; KAMBAYASHI, Junichi et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 211-236, issn 0171-2004, 26 p.Article

Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinaseMCEWAN, David G; BRUNTON, Valerie G; BAILLIE, George S et al.Cancer research (Baltimore). 2007, Vol 67, Num 11, pp 5248-5257, issn 0008-5472, 10 p.Article

The GAF-Tandem Domain of Phosphodiesterase 5 as a Potential Drug TargetSCHULTZ, Joachim E; DUNKERN, Torsten; GAWLITTA-GORKA, Elvira et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 151-166, issn 0171-2004, 16 p.Article

Role of Phosphodiesterases in Adult-Onset Pulmonary Arterial HypertensionMURRAY, F; MACLEAN, M. R; INSEL, P. A et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 279-305, issn 0171-2004, 27 p.Article

Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse Model of Duchenne Muscular DystrophyPERCIVAL, Justin M; ADAMO, Candace M; BEAVO, Joseph A et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 323-344, issn 0171-2004, 22 p.Article

Protein Kinase A Type I and Type II Define Distinct Intracellular Signaling CompartmentsDI BENEDETTO, Giulietta; ZOCCARATO, Anna; LISSANDRON, Valentina et al.Circulation research. 2008, Vol 103, Num 8, pp 836-844, issn 0009-7330, 9 p.Article

A Fission Yeast-Based Platform for Phosphodiesterase Inhibitor HTSs and Analyses of Phosphodiesterase ActivityDEMIRBAS, Didem; CEYHAN, Ozge; WYMAN, Arlene R et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 135-149, issn 0171-2004, 15 p.Article

Phosphodiesterase Inhibitors: History of PharmacologySCHUDT, Christian; HATZELMANN, Armin; BEUME, Rolf et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 1-46, issn 0171-2004, 46 p.Article